Epidermal Growth Factor Receptor Signaling in Adenocarcinomas With Bronchioloalveolar Components

Annals of Thoracic Surgery

Volumn 85, Issue 1, 2008, Pages 216-223

  Sarkaria, Inderpal S ^a   Zakowski, Maureen F ^a   Pham, Duykhanh ^a   Hezel, Michael ^a   Ebright, Michael I ^a   Chuai, Shaokun ^a   Venkatraman, Ennapadam S ^a   Kris, Mark G ^a   Rusch, Valerie W ^a   Singh, Bhuvanesh ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; TUMOR MARKER;

ARTICLE; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SMOKING;

ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ADULT; AGED; BIOPSY, NEEDLE; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PNEUMONECTOMY; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 37249059840     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2007.07.046     Document Type: Article

References (33)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
2. Travis W.D., Colby T.V., Corrin B., Shimosato Y., Brambilla E., and Sobin L.H. Histologic typing of lung and pleural tumors. 3rd ed. (1999), Springer-Verlag, Berlin 155
3. Barkley J.E., and Green M.R. Bronchioloalveolar carcinoma. J Clin Oncol 14 (1996) 2377-2386
4. Miller V.A., Kris M.G., Shah N., et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 22 (2004) 1103-1109
5. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
6. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
7. Pao W., Miller V., Zakowski M., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101 (2004) 13306-13311
8. Jorissen R.N., Walker F., Pouliot N., Garrett T.P., Ward C.W., and Burgess A.W. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 284 (2003) 31-53
9. Scagliotti G.V., Selvaggi G., Novello S., and Hirsch F.R. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res 10 Suppl (2004) 4227s-4232s
10. Ebright M.I., Zakowski M.F., Martin J., et al. Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma. Ann Thorac Surg 74 (2002) 1640-1647
11. Sarkaria I.S., Pham D., Ghossein R.A., et al. SCCRO expression correlates with invasive progression in bronchioloalveolar carcinoma. Ann Thorac Surg 78 (2004) 1734-1741
12. th ed. (1998), Lippincott-Raven, Philadelphia
13. Martini N., and Melamed M.R. Multiple primary lung cancers. J Thorac Cardiovasc Surg 70 (1975) 606-612
14. Dutu T., Michiels S., Fouret P., et al. Differential expression of biomarkers in lung adenocarcinoma: a comparative study between smokers and never-smokers. Ann Oncol 16 (2005) 1906-1914
15. Choe G., Horvath S., Cloughesy T.F., et al. Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 63 (2003) 2742-2746
16. Hoos A., Urist M.J., Stojadinovic A., et al. Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol 158 (2001) 1245-1251
17. Kris M.G., Natale R.B., Herbst R.S., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290 (2003) 2149-2158
18. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 (2005) 123-132
19. Parra H.S., Cavina R., Latteri F., et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa,' ZD1839) in non-small-cell lung cancer. Br J Cancer 91 (2004) 208-212
20. Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). [corrected]. J Clin Oncol 21 (2003) 2237-2246
21. Erman M., Grunenwald D., Penault-Llorca F., et al. Epidermal growth factor receptor, HER-2/neu and related pathways in lung adenocarcinomas with bronchioloalveolar features. Lung Cancer 47 (2005) 315-323
22. Hirsch F.R., Varella-Garcia M., Bunn Jr. P.A., et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21 (2003) 3798-3807
23. Hirsch F.R., Varella-Garcia M., McCoy J., et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 23 (2005) 6838-6845
24. Aoyagi Y., Yokose T., Minami Y., et al. Accumulation of losses of heterozygosity and multistep carcinogenesis in pulmonary adenocarcinoma. Cancer Res 61 (2001) 7950-7954
25. Forgacs E., Biesterveld E.J., Sekido Y., et al. Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene 17 (1998) 1557-1565
26. Rusch V.W., Reuter V.E., Kris M.G., et al. Ras oncogene point mutation: an infrequent event in bronchioloalveolar cancer. J Thorac Cardiovasc Surg 104 (1992) 1465-1469
27. Vicent S., Lopez-Picazo J.M., Toledo G., et al. ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours. Br J Cancer 90 (2004) 1047-1052
28. Cappuzzo F., Magrini E., Ceresoli G.L., et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 96 (2004) 1133-1141
29. Veale D., Ashcroft T., Marsh C., Gibson G.J., and Harris A.L. Epidermal growth factor receptors in non-small cell lung cancer. Br J Cancer 55 (1987) 513-516
30. Fontanini G., Vignati S., Bigini D., et al. Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. Eur J Cancer 31A (1995) 178-183
31. Rusch V., Klimstra D., Venkatraman E., Pisters P.W., Langenfeld J., and Dmitrovsky E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 3 (1997) 515-522
32. Dazzi H., Hasleton P.S., Thatcher N., et al. Expression of epidermal growth factor receptor (EGF-R) in non-small cell lung cancer. Use of archival tissue and correlation of EGF-R with histology, tumour size, node status and survival. Br J Cancer 59 (1989) 746-749
33. Meert A.P., Martin B., Delmotte P., et al. The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J 20 (2002) 975-981